Threshold value of anti-Mullerian hormone for the diagnosis of polycystic ovary syndrome in Chinese women
- PMID: 30153296
- PMCID: PMC6112651
- DOI: 10.1371/journal.pone.0203129
Threshold value of anti-Mullerian hormone for the diagnosis of polycystic ovary syndrome in Chinese women
Abstract
Objective: We intended to establish the threshold for anti-Mullerian hormone (AMH) in the diagnosis of polycystic ovary syndrome (PCOS) in China.
Methods: A total of 771 women (653 with PCOS and 118 healthy controls) were enrolled. The serum AMH, follicle-stimulating hormone (FSH), luteinizing hormone (LH), FSH/LH, prolactin, estradiol, testosterone (T), dehydroepiandrosterone sulfate (DHEA-S), sex hormone-binding globulin (SHBG), 17α-OH progesterone (17α-OHP), fasting insulin (INS), fasting glucose, free androgen index (FAI%) and homeostasis model assessment for insulin resistance (HOMA-IR) index were analyzed, and the diagnostic utility of AMH, LH/FSH, T and INS was established using receiver operator characteristic (ROC) curves. With AMH, LH/FSH, T and INS as independent variables, a logistic regression model was established, and the ROC curve for combined detection was fitted with the probability value of the model.
Results: The serum level of FSH, LH, LH/FSH, AMH, FAI%, 17α-OHP, fasting INS, T, SHBG, DHEA-S and HOMA-IR were altered in the PCOS patients. The best compromise between sensitivity and specificity was found at an AMH cut-off level of 8.16 ng/ml and 5.89 ng/ml for the age groups 20-29 and 30-39 years, with the corresponding area under the curve being 0.846 and 0.865 respectively. The area under the ROC curve for combined detection was 0.951, which was significantly greater than that of each index. Finally, the concentration of AMH was associated with FSH, LH, LH/FSH, T, and ovarian volume in PCOS patients.
Conclusion: The optimal AMH diagnostic threshold for PCOS was 8.16 ng/ml (20-29 years) and 5.89 ng/ml (30-39 years) in the Chinese population of this study. Moreover, serum AMH, LH/FSH, T and INS could be used in combination to improve the diagnostic specificity and sensitivity for the detection of PCOS.
Conflict of interest statement
The authors have declared that no competing interests exist.
Similar articles
-
The Relevant Hormonal Levels and Diagnostic Features of Polycystic Ovary Syndrome in Adolescents.J Clin Med. 2020 Jun 11;9(6):1831. doi: 10.3390/jcm9061831. J Clin Med. 2020. PMID: 32545404 Free PMC article.
-
Elevated serum levels of anti-Müllerian hormone can be introduced as a new diagnostic marker for polycystic ovary syndrome.Acta Obstet Gynecol Scand. 2013 Dec;92(12):1369-74. doi: 10.1111/aogs.12247. Epub 2013 Oct 15. Acta Obstet Gynecol Scand. 2013. PMID: 23980726
-
Anti-Müllerian Hormone and Inhibin-A, but not Inhibin-B or Insulin-Like Peptide-3, may be Used as Surrogates in the Diagnosis of Polycystic Ovary Syndrome in Adolescents: Preliminary Results.J Clin Res Pediatr Endocrinol. 2016 Sep 1;8(3):288-97. doi: 10.4274/jcrpe.3253. Epub 2016 Apr 29. J Clin Res Pediatr Endocrinol. 2016. PMID: 27125339 Free PMC article.
-
The role of anti-Müllerian hormone in the pathogenesis and pathophysiological characteristics of polycystic ovary syndrome.Eur J Obstet Gynecol Reprod Biol. 2016 Apr;199:82-7. doi: 10.1016/j.ejogrb.2016.01.029. Epub 2016 Feb 10. Eur J Obstet Gynecol Reprod Biol. 2016. PMID: 26914398 Review.
-
Anti-müllerian hormone as a diagnostic biomarker for polycystic ovary syndrome and polycystic ovarian morphology: a systematic review and meta-analysis.Fertil Steril. 2024 Oct;122(4):727-739. doi: 10.1016/j.fertnstert.2024.05.163. Epub 2024 Jun 27. Fertil Steril. 2024. PMID: 38944177
Cited by
-
Anti-Müllerian hormone (AMH) in the Diagnosis of Menstrual Disturbance Due to Polycystic Ovarian Syndrome.Front Endocrinol (Lausanne). 2019 Sep 26;10:656. doi: 10.3389/fendo.2019.00656. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31616381 Free PMC article.
-
Serum Anti-Müllerian Hormone in the Diagnosis of Polycystic Ovary Syndrome in Association with Clinical Symptoms.Diagnostics (Basel). 2019 Oct 1;9(4):136. doi: 10.3390/diagnostics9040136. Diagnostics (Basel). 2019. PMID: 31581541 Free PMC article.
-
The Relationship Between Anti-Müllerian Hormone and Body Composition Components in Patients With Polycystic Ovary Syndrome of Reproductive Age.Reprod Sci. 2024 Sep;31(9):2843-2848. doi: 10.1007/s43032-024-01561-4. Epub 2024 Apr 23. Reprod Sci. 2024. PMID: 38653855
-
Efficacy of serum anti-mullerian hormone (AMH) levels for prediction of polycystic ovary syndrome (PCOS) and its association with clinical, biochemical and hormonal parameters.Indian J Clin Biochem. 2023 Oct;38(4):457-465. doi: 10.1007/s12291-022-01058-4. Epub 2022 Sep 6. Indian J Clin Biochem. 2023. PMID: 37746534 Free PMC article.
-
The alterations of circulating mucosal-associated invariant T cells in polycystic ovary syndrome.Front Endocrinol (Lausanne). 2022 Nov 28;13:1038184. doi: 10.3389/fendo.2022.1038184. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36518256 Free PMC article.
References
-
- Speroff L. Clinical gynecologic endocrinology and infertility. Lippincott Williams. 2005;12: 485–513.
-
- Bako AU, Morad S, Atiomo WA. Polycystic ovary syndrome: an overview. Rev Gynecol Pract. 2005;5: 115–22.
-
- Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S, Panidis D. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. American Journal of Physiology—Endocrinology & Metabolism, 2009, 296, E238–E243. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous